Sanofi has agreed to purchase its own shares worth €2bn ($2.08bn), part of a $5.1bn share buyback initiative in 2025.

That gives it an advantage over other biologics for severe asthma, such as Sanofi/Regeneron's IL-4/IL-13 inhibitor Dupixent (dupilumab ... has attributed to complex administration and a demanding ...

the US FDA has approved Sanofi and Regeneron's Dupixent (dupilumab) for COPD - as has China's National Medical Products Administration (NMPA), which announced its approval the same day.

Teaser: Off-label systemic agents may treat inflammatory autoimmune vulvar diseases such as lichen sclerosus and lichen ...

The Inflation Reduction Act (IRA), passed in 2022, made changes to the way drugs are covered and reimbursed in Medicare.

Enveda, a biotechnology company using AI to translate nature into new medicines, is proud to announce testing of its lead asset, ENV-294, in a second indication: asthma. This novel therapeutic, ...

The international consulting firm Clarivate makes its bet among the novelties ready for the medicine cabinet this year: three ...

Background: Rising use of sunscreen products has led to increased reporting of adverse reactions to sunscreens. Objective: To investigate possible photoallergic reactions in patients who ...

CYP shows a carcinogenic and teratogenic activity (86). As a result CYP administration is not allowed in pregnancy and breastfeeding (101). Moreover, temporary or permanent gonadal dysfunction has ...